Staying with vertigo, there is a lack of consensus as to the optimum dosage and method of administration of intratympanic gentamicin therapy for Ménière's disease. Watson and colleagues present their experience, and advocate a low-dose regime as being effective, while potentially causing less cochlear toxicity and hearing loss. 3 Other authors have suggested a much more intense high-dose regime as effective in producing both short-and long-term improvements in Ménière's disease patients. 4 Finally, in this issue, we once again feature the everpresent risk of litigation in modern medical practice. 5, 6 As Metcalfe and colleagues point out in their review, litigation in surgery is increasing and liabilities are becoming unsustainable. 5 In the National Health Service in England, claims within ENT are relatively infrequent, but potentially very costly. Over half of claims relate to the five most common areas of litigation (i.e. failure or delay in diagnosis, intra-operative problems, failure or delay in treatment, and inappropriate treatment). Increasing claims are occurring despite initiatives such as the World Health Organization's 'Safe Surgery Saves Lives'.
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